Please assess the completion status of the following clinical trial:

Trial Title: Viaskin Pertussis Vaccine Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has provided written informed consent before enrollment;~* Adult male or female, ages 18 to 40 years (inclusive) at the time of enrollment;~* Non-pregnant, non-lactating female;~* Free of clinically significant health problems, as determined by pertinent medical history and clinical examination at study screening;~* With documented history of pertussis immunization (at least 4 doses);~* Women of childbearing potential with a negative pregnancy test at entry;~* Females of childbearing potential who are willing to use an effective method of contraception.~Exclusion Criteria:~* Prior dTpa immunization within the last 10 years or prior dT immunization within the last 2 years, or any other investigational vaccine likely to impact on interpretation of the trial data;~* Suspected or confirmed pertussis infection within the last 10 years or documented pertussis infection in a household member within the last 10 years;~* Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines) or ongoing participation in another clinical interventional trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Viaskin PT 25 mcg (Type: EXPERIMENTAL): Viaskin PT 25 mcg
- Viaskin PT 50 mcg (Type: EXPERIMENTAL): Viaskin PT 50 mcg
- Viaskin PT Placebo (Type: PLACEBO_COMPARATOR): Viaskin PT Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).